Patents by Inventor Hailing Hsu

Hailing Hsu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Alpha-4-beta-7 heterodimer specific antagonist antibody
    Patent number: 8871490
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: April 22, 2013
    Date of Patent: October 28, 2014
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Ian Foltz, Frederick Jacobsen, Taruna Arora
  • PROTEINS SPECIFIC FOR BAFF AND B7RP1
    Publication number: 20140302036
    Abstract: Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.
    Type: Application
    Filed: March 10, 2014
    Publication date: October 9, 2014
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ming ZHANG, Gunasekaran KANNAN, Frederick W. JACOBSEN, Wayne TSUJI
  • PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
    Publication number: 20140234334
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Application
    Filed: July 9, 2013
    Publication date: August 21, 2014
    Applicant: AMGEN INC.
    Inventors: Hosung MIN, Hailing HSU, Fei XIONG
  • Peptides and related molecules that bind to TALL-1
    Patent number: 8507426
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ?ID?NO:?100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ?ID?NO:?104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ?ID?NO:?105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ?ID?NO:?106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ?ID?NO:?107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ?ID?NO:?109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: August 13, 2013
    Assignee: Amgen, Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • Alpha-4-beta-7 heterodimer specific antagonist antibody
    Patent number: 8454961
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: June 4, 2013
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • Alpha-4-beta-7 heterodimer specific antagonist antibody
    Patent number: 8454962
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: June 4, 2013
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • Alpha-4 beta-7 heterodimer specific antagonist antibody
    Patent number: 8444981
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Grant
    Filed: March 16, 2010
    Date of Patent: May 21, 2013
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY
    Publication number: 20120183561
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 19, 2012
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • ALPHA-4-BETA-7 HETERODIMER SPECIFIC ANTAGONIST ANTIBODY
    Publication number: 20120177662
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 22, 2012
    Publication date: July 12, 2012
    Applicant: Amgen Inc.
    Inventors: Hailing HSU, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • ALPHA-4 BETA-7 HETERODIMER SPECIFIC
    Publication number: 20100254975
    Abstract: There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.
    Type: Application
    Filed: March 16, 2010
    Publication date: October 7, 2010
    Applicant: Amgen Inc.
    Inventors: Hailing Hsu, Ian Foltz, Taruna Arora, Frederick W. Jacobsen
  • PEPTIDES AND RELATED MOLECULES THAT BIND TO TALL-1
    Publication number: 20100240590
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5DC7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Ld16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Application
    Filed: May 26, 2010
    Publication date: September 23, 2010
    Inventors: Hosung MIN, Hailing Hsu, Fei Xiong
  • Peptides and related molecules that bind to TALL-1
    Patent number: 7737111
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: June 15, 2010
    Assignee: Amgen, Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators
    Patent number: 7544519
    Abstract: The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.
    Type: Grant
    Filed: July 13, 2004
    Date of Patent: June 9, 2009
    Assignee: Amgen Inc.
    Inventors: Hailing Hsu, Scott Kenneth Wooden, William James Boyle
  • Peptides and related molecules that bind to TALL-1
    Patent number: 7259137
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO: 100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO: 104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO: 105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO: 106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO: 107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO: 109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: May 13, 2002
    Date of Patent: August 21, 2007
    Assignee: Amgen Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • TALL-1 receptor molecules and uses thereof
    Patent number: 7256015
    Abstract: The present invention provides tumor necrosis factor and apoptosis ligand-related leukocyte-expressed ligand 1 receptor (TALL-1R) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing TALL-1R polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with TALL-1R polypeptides.
    Type: Grant
    Filed: September 20, 2002
    Date of Patent: August 14, 2007
    Assignee: Amgen Inc.
    Inventor: Hailing Hsu
  • Methods for detecting NTR3 nucleic acids by hybridization
    Patent number: 7118863
    Abstract: The present invention provides a purified polynucleotide encoding a novel receptor, designated NTR3, which belongs to the TNF receptor gene superfamily; to purified NTR3 polypeptide molecules; to antibodies that bind NTR3; to materials comprising such molecules; and to methods of using such molecules.
    Type: Grant
    Filed: April 19, 2002
    Date of Patent: October 10, 2006
    Assignee: Amgen, Inc.
    Inventor: Hailing Hsu
  • Peptides and related molecules that bind to TALL-1
    Publication number: 20060135431
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Application
    Filed: November 10, 2005
    Publication date: June 22, 2006
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong
  • RIP: a human protein involved in tumor necrosis factor signal transduction
    Patent number: 7029871
    Abstract: The invention relates to a human Receptor Interacting Protein (hRIP), nucleic acids which encode hRIP and methods of using the subject compositions; in particular, methods such as hRIP-based in vitro binding assays and phosphorylation assays for screening chemical libraries for lead compounds for pharmacological agents.
    Type: Grant
    Filed: January 9, 2001
    Date of Patent: April 18, 2006
    Assignee: Amgen, Inc.
    Inventors: Vijay R. Baichwal, Jianing Huang, Hailing Hsu, David V. Goeddel
  • Fhm, a novel member of the TNF ligand supergene family
    Patent number: 6852839
    Abstract: The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.
    Type: Grant
    Filed: November 1, 2002
    Date of Patent: February 8, 2005
    Assignee: Amgen, Inc.
    Inventors: Hailing Hsu, Scott Kenneth Wooden, William James Boyle
  • Fhm a novel member of the TNF ligand supergene family: antibody materials and methods
    Publication number: 20040265913
    Abstract: The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.
    Type: Application
    Filed: July 13, 2004
    Publication date: December 30, 2004
    Inventors: Hailing Hsu, Scott Kenneth Wooden, William James Boyle